glp-1 kidney pain receptor agonists in patients with chronic disease and either overweight or obesity Glucagon-like Peptide Receptor Agonists and

Theres really nothing surprising about it, and theres nothing to be alarmed about this

False Claims: Marketing can trick people into believing supplements work just like prescriptions

While the B12 component may reduce nausea severity, it does not eliminate it entirely

In patients with T2DM who are overweight or obese, glucagonlike peptide 1 (GLP-1) and dual GLP-1/gastric inhibitory peptide (GIP) agonists are used as adjunct or alternative therapies given their dual benefits for insulin sensitivity and weight loss

This underscores that for an obese hypertensive patient, a GLP-1 RA can provide an antihypertensive benefit comparable to adding a mild BP drug, especially as part of a weight-centric strategy